Markus D Siegelin, MD

Specialties:
Anatomic Pathology, Pathology - Anatomic
Accepting New Patients
Profile Headshot

Overview

Academic Appointments

  • Associate Professor of Pathology & Cell Biology

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Languages

  • German

Gender

  • Male

Schedule an Appointment

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Insurance Accepted

Cigna

  • EPO
  • Great West (National)
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross/Blue Shield

  • HMO

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

RiverSpring

  • Special Needs

UnitedHealthcare

  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, 2005 Johann Wolfgang Goethe University Faculty of Medicine (Germany)
  • 2005 Johann Wolfgang Goethe University Medical School
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Residency: 2013 NewYork-Presbyterian/Columbia University Medical C
  • Fellowship: Ruprecht Karl University (Germany)

Board Certifications

  • Anatomic Pathology

Honors & Awards

  • 2007 Rudi-Busse Dissertation Award for the best doctoral thesis in 2007, Johann-Wolfgang-Goethe University, Frankfurt am Main, Germany
  • 2007 Young Investigator Award, Ruprecht-Karls-University, Heidelberg, Germany
  • 2009 Post-Doctoral Research Fellowship awarded by German Research Foundation.
  • 2012 Stowell-Orbison Award, United States & Canadian Academy of Pathology, Vancouver, BC, Canada.
  • 2013 American Association for Cancer Research (AACR) and National Brain Tumor Society Career Development Award for Translational Brain Tumor Research
  • 2013 Translational Grant Program, American Brain Tumor Association (ABTA)
  • 2014-2019 National Institue of Health, NINDS, K08 Career Development Award
  • 2016-2021 National Institue of Health, NINDS, R01 Research Grant
  • 2016 BCURED Fighting Brain Cancer Award
  • 2018-2023 National Institute of Health, NINDS, R01 Research Grant on synthetic lethal interactions in IDH1 mutant gliomas
  • 2017 Louis V. Gerstner, Jr. Scholar
  • 2017 ABTA Discovery Grant
  • 2020 Schaefer Research Scholar
  • 2021-2026 National Institute of Health, NINDS, R01 Research Grant on HDAC inhibitors and tumor metabolism in glioblastoma
  • 2021 ABTA Discovery Grant

Research

Research Interests

  • Establishing Mechanisms of Drug Resistance in Brain Tumors
  • Identification of Novel Drug Combination Therapies for Brain Tumors
  • Targeting Cell Death Mechanisms in Brain Tumors
  • Targeting Tumor Cell Metabolism and The Epigenome for Brain Tumor Therapy

Selected Publications

  • Nguyen TTT, Shang E, Shu C, Kim S, Mela A, Humala N, Mahajan A, Yang HW, Akman HO, Quinzii CM, Zhang G, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nat Commun. 2021 Sep 1;12(1):5203. doi: 10.1038/s41467-021-25501-x.
  • Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, Bianchetti E, Mela A, Humala N, Mahajan A, Harmanci AO, Lei Z, Maienschein-Cline M, Quinzii CM, Westhoff MA, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest. 2020 Jul 1;130(7):3699-3716. doi: 10.1172/JCI129049.
  • Zhang Y, Nguyen TTT, Shang E, Mela A, Humala N, Mahajan A, Zhao J, Shu C, Torrini C, Sanchez-Quintero MJ, Kleiner G, Bianchetti E, Westhoff MA, Quinzii CM, Karpel-Massler G, Bruce JN, Canoll P, Siegelin MD. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma. Cancer Res. 2020 Jan 1;80(1):30-43. doi: 10.1158/0008-5472.CAN-19-1389. 
  • Karpel-Massler G, Ishida CT, Bianchetti E, Shu C, Perez-Lorenzo R, Horst B, Banu M, Roth KA, Bruce JN, Canoll P, Altieri DC, Siegelin MD. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res. 2017 Jul 1;77(13):3513-3526. doi: 10.1158/0008-5472.CAN-16-3424.
  • Karpel-Massler G, Ishida CT, Bianchetti E, Zhang Y, Shu C, Tsujiuchi T, Banu MA, Garcia F, Roth KA, Bruce JN, Canoll P, Siegelin MD. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.